Epizyme’s (EPZM) “Outperform” Rating Reaffirmed at Leerink Swann

Leerink Swann reaffirmed their outperform rating on shares of Epizyme, Inc. (NASDAQ:EPZM) in a research report released on Thursday, November 2nd. They currently have a $22.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $28.00.

Several other research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Epizyme from a hold rating to a buy rating and set a $16.00 target price on the stock in a research report on Wednesday, July 12th. BidaskClub cut shares of Epizyme from a hold rating to a sell rating in a research report on Wednesday, July 19th. Royal Bank Of Canada cut shares of Epizyme from an outperform rating to a sector perform rating and decreased their target price for the company from $20.00 to $16.00 in a research report on Thursday, November 2nd. Cann restated a buy rating and set a $26.00 target price on shares of Epizyme in a research report on Thursday, November 2nd. Finally, Jefferies Group LLC initiated coverage on shares of Epizyme in a research report on Wednesday, September 20th. They issued a buy rating and a $23.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Epizyme presently has an average rating of Buy and a consensus price target of $22.67.

Shares of Epizyme (NASDAQ:EPZM) opened at $12.85 on Thursday. Epizyme has a 1 year low of $9.30 and a 1 year high of $20.45.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02. equities analysts expect that Epizyme will post -2.23 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by BBNS and is the property of of BBNS. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://baseballnewssource.com/markets/epizyme-inc-epzm-receives-outperform-rating-from-leerink-swann/1752095.html.

In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the completion of the transaction, the insider now owns 22,228 shares of the company’s stock, valued at $348,535.04. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David M. Mott purchased 200,000 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was bought at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 45,000 shares of company stock worth $733,950. Insiders own 25.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. raised its holdings in shares of Epizyme by 0.5% during the first quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock worth $1,615,000 after purchasing an additional 515 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Epizyme by 8.9% during the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 795 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Epizyme by 3.3% during the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 1,068 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Epizyme by 2.6% during the second quarter. Rhumbline Advisers now owns 50,140 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 1,257 shares during the last quarter. Finally, American International Group Inc. raised its holdings in shares of Epizyme by 7.1% during the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after purchasing an additional 1,638 shares during the last quarter. 78.00% of the stock is owned by hedge funds and other institutional investors.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.